J Cancer 2015; 6(2):139-143. doi:10.7150/jca.10429

Short Research Communication

Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report

Jonai Pujol-Gimenez1, Fátima Pérez de Heredia2, Miguel Angel Idoate3, Rachel Airley4, María Pilar Lostao1 *, Andrew Robert Evans5*✉

1. Department of Nutrition, Food Science and Physiology, School of Pharmacy, University of Navarra, Pamplona, Spain.
2. School of Natural Sciences and Psychology, Liverpool John Moores University, Liverpool, UK.
3. Department of Pathology, Clínica Universidad de Navarra, Av. Pío XII 36, 31008 Pamplona, Spain.
4. School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
5. School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
* Both authors have contributed equally to this work.

Abstract

Background: Recent studies proposed GLUT12 to be a major glucose transporter involved in the glycolytic metabolism of cancer cells.

Methods: GLUT12 expression was determined by immunohistochemistry in a selection of cancer cell lines and a tumour spheroid model.

Results: GLUT12 expression was high in A549 and RH-36; low in HT29; and absent in NB-EB cancer cell lines. GLUT12 expression was located in the necrotic centre of HT29 spheroids, which is characterised by anaerobic metabolism.

Conclusion: The data supports the involvement of GLUT12 in the glycolytic metabolism of cancer cells and therefore, its potential as a novel therapeutic target for cancer treatment.

Keywords: GLUT12, Cancer cell lines, Spheroid, Immunohistochemistry, Glycolytic metabolism.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Pujol-Gimenez J, de Heredia FP, Idoate MA, Airley R, Lostao MP, Evans AR. Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report. J Cancer 2015; 6(2):139-143. doi:10.7150/jca.10429. Available from http://www.jcancer.org/v06p0139.htm